__

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms

DG FastChannel®, Inc. (NASDAQ: DGIT) reported that it will report its second quarter financial results before the market opens on Wednesday, August 4, 2010. The Company will host a conference call and webcast at 10:00 a.m. ET that morning to review the results.

Highwoods Properties (NYSE: HIW) Board of Directors declared a cash dividend of $0.425 per share of common stock for the quarter ended June 30, 2010, which equates to an annual dividend of $1.70 per share and is payable on September 8, 2010 to shareholders of record as of August 16, 2010.

RSC Holdings Inc. (NYSE: RRR), one of the largest equipment rental providers in North America, reported financial results for the quarter ended June 30, 2010. Total revenue was $301 million and rental revenue was $260 million, compared with $327 million and $271 million, respectively, for the same period last year. The company reported a second quarter net loss of $22 million, or $0.21 per diluted share, compared with a net loss of $11 million, or $0.11 per diluted share, for the second quarter 2009.

Hypercom Corporation (NYSE: HYC) has scheduled its conference call to discuss second quarter 2010 results for Wednesday, August 4, at 4:30 p.m. ET. The call will be simultaneously webcast.

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).

__

AMRI (NASDAQ: AMRI) has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI’s Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Service providers of every size and type are choosing Brocade (Nasdaq:BRCD) solutions to develop networks that deliver increasingly advanced combinations of voice, data, video and mobility (quad-play) services to businesses and consumers. These providers list reliability, low total cost of ownership (TCO) and a collaborative relationship as fundamental reasons for working with Brocade as their network provider of choice.

Morgan Stanley (NYSE: MS) today reported income of $1.4 billion, or $0.80 per diluted share, from continuing operations applicable to Morgan Stanley for the quarter ended June 30, 2010 compared with a loss of $138 million, or $1.36 per diluted share, for the same period a year ago. Net revenues were $8.0 billion for the current quarter compared with $5.2 billion a year ago. Net revenues in the current quarter included positive revenue of $750 million compared with negative revenue of $2.3 billion in the prior year’s second quarter related to Morgan Stanley’s debt-related credit spreads (DVA).1, 2 Comparisons of current quarter results with the prior year were affected by the results of Morgan Stanley Smith Barney (MSSB),3 which closed on May 31, 2009. The results for the quarter also included a tax benefit of $345 million, or $0.20 per diluted share, associated with the remeasurement of tax reserves based on the status of federal and state examinations. The annualized return on average common equity from continuing operations was 12.2% in the quarter.

Crown Equity Holdings, Inc. (OTCBB: CRWE) recently reported that it will implement a forward stock split of its common stock on a one-for-ten basis. In connection with this forward split, the Company will increase its authorized shares from 500,000,000 to 1,000,000,000 shares. An effective date for the split has not been determined but is expected to occur in late July for shareholders of record as of July 15, 2010. Ken Bosket, CEO of Crown Equity Holdings, Inc., stated, “It has been determined that this 1 - 10 forward split should benefit our shareholders by increasing the amount of liquidity available to investors therefore giving us the potential to attract more buyers of an institutional nature. Considering the huge increase in income Crown Equity Holdings, Inc. has experienced this past year, we are confident our future projected revenue stream will more than support this financial strategy.”

The GEO Group (NYSE: GEO) (“GEO”) reported that it has signed a contract with the State of Georgia, Department of Corrections for the development and operation of a new 1,500-bed correctional facility (the “Facility”) to be located in Milledgeville, Georgia.

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).

__

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

SLM Corporation (NYSE: SLM), commonly known as Sallie Mae, reported core earnings net income of $209 million ($.39 per diluted share) for the second quarter 2010, which included an after-tax gain of $57 million ($.11 per diluted share) from $1.4 billion of unsecured debt repurchases. These results compare to core earnings net income of $170 million ($.31 per diluted share) in the second quarter 2009. On a GAAP basis, net income was $338 million ($.63 per diluted share) in the second-quarter 2010, vs. a net loss of $123 million ($.32 per diluted share) in the year-ago period.

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), reported the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised their option to purchase an additional approximately 642,000 shares of common stock. As a result, BioMimetic sold a total of approximately 5.64 million shares of its common stock at a price to the public of $8.50 per share. After underwriting discounts and commissions and estimated offering expenses, BioMimetic received net proceeds of approximately $45 million. These shares were sold pursuant to BioMimetic’s existing shelf registration statement, the prospectus contained therein and the prospectus supplement as filed with the Securities Exchange Commission.

Palm Harbor Homes, Inc. (NASDAQ: PHHM) reported financial results for the first quarter ended June 25, 2010. Net sales for the first quarter of fiscal 2011 totaled $84.3 million compared with $82.4 million for the first quarter of fiscal 2010. Palm Harbor reported an operating loss of $2.0 million for the first quarter of fiscal 2011 compared with an operating loss of $5.1 million in the same period last year. Net loss for the first quarter of fiscal 2011 totaled $5.7 million, or $0.25 per share, compared with a net loss of $10.0 million, or $0.44 per share, a year ago.

United Rentals, Inc. (NYSE: URI) reported financial results for the second quarter 2010. Total revenue was $557 million and rental revenue was $450 million, compared with $615 million and $454 million, respectively, for the same period last year. Operating income was $59 million, compared with $5 million for the same period last year.

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).

__

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Pennsylvania Real Estate Investment Trust (NYSE: PEI) intends to release its financial results for the second quarter ended June 30, 2010 before market trading begins on Tuesday, August 3, 2010.

Ramius Value and Opportunity Advisors LLC, a subsidiary of Ramius LLC (collectively, “Ramius”), reported that it has sent a letter to the Board of Directors of Cypress Bioscience, Inc. (“Cypress” or “the Company”) (NASDAQ: CYPB) outlining an offer to acquire all of the outstanding shares of the Company that it does not already own for $4.00 per share in cash. The Ramius offer described in the letter represents a 60% premium over the July 16, 2010, closing price and a 74% premium over the average closing price since the acquisition of BioLineRx’s BL-1020 drug. Ramius currently owns 9.9% of the outstanding common stock of Cypress, making it one of the Company’s largest shareholders.

Geron Corporation (Nasdaq:GERN) reported enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).

__

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

The Clough Global Equity Fund (NYSE Amex: GLQ) declared a quarterly cash distribution of $0.29 per common share for July 2010. The dividend will be payable on July 30, 2010 to shareholders of record on July 26, 2010.

ValueRich, Inc. (NYSE Amex: IVA) reported that the Company has substantially increased its cash position due to the sale of one of its single-family home lots and also the release of funds back to ValueRich that secured a performance bond to satisfy an outstanding wetland mitigation issue with the South Florida Water Management District. The finished lot was sold for $300,000 and was one (1) of eighty-two (82) single-family home lots ValueRich acquired with its original purchase of the Tesoro Preserve Development assets. ValueRich also received approximately $540,000 in funds released from an escrow account that was held to guarantee the resolution of an outstanding wetland mitigation issue located within the Tesoro Preserve Development that was not satisfied by the original developer. ValueRich engaged Culpepper and Terpening, Inc. and RL Weigt Environmental Consultants to complete the engineering and environmental work and the Company purchased 3.3 off site wetland mitigation credits from Bluefield Ranch Mitigation Bank in order to bring the Tesoro Preserve development into regulatory compliance with the South Florida Water Management District.

Aetna (NYSE: AET) reported it will support Judge Glenda Hatchett’s ParentPowerNow! anti-obesity program. “Parent Power Now!” is an online community of people interested in working together and learning more about parenting. Aetna has awarded a $75,000 grant and will provide health content for the ParentPowerNow! website, guest speakers to address healthy living on Judge Hatchett’s live website radio program, and support for health events scheduled around the country.

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).